These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21528623)

  • 1. Epidemiology of clostridium difficile and vancomycin-resistant Enterococcus colonization in patients on a spinal cord injury unit.
    Dumford DM; Nerandzic M; Chang S; Richmond MA; Donskey C
    J Spinal Cord Med; 2011; 34(1):22-7. PubMed ID: 21528623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease.
    Sethi AK; Al-Nassir WN; Nerandzic MM; Donskey CJ
    Infect Control Hosp Epidemiol; 2009 Jan; 30(1):13-7. PubMed ID: 19046063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.
    Riggs MM; Sethi AK; Zabarsky TF; Eckstein EC; Jump RL; Donskey CJ
    Clin Infect Dis; 2007 Oct; 45(8):992-8. PubMed ID: 17879913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical model of the impact of a nonantibiotic treatment for Clostridium difficile on the endemic prevalence of vancomycin-resistant enterococci in a hospital setting.
    Grima DT; Webb GF; D'Agata EM
    Comput Math Methods Med; 2012; 2012():605861. PubMed ID: 22291852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization.
    Choi HK; Kim KH; Lee SH; Lee SJ
    J Korean Med Sci; 2011 Jul; 26(7):859-64. PubMed ID: 21738336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
    Miller M; Bernard L; Thompson M; Grima D; Pepin J
    Infect Control Hosp Epidemiol; 2010 Jul; 31(7):710-5. PubMed ID: 20518636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.
    Al-Nassir WN; Sethi AK; Li Y; Pultz MJ; Riggs MM; Donskey CJ
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2403-6. PubMed ID: 18443120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection.
    Sethi AK; Al-Nassir WN; Nerandzic MM; Bobulsky GS; Donskey CJ
    Infect Control Hosp Epidemiol; 2010 Jan; 31(1):21-7. PubMed ID: 19929371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile and vancomycin-resistant enterococcus: the new nosocomial alliance.
    Poduval RD; Kamath RP; Corpuz M; Norkus EP; Pitchumoni CS
    Am J Gastroenterol; 2000 Dec; 95(12):3513-5. PubMed ID: 11151886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission.
    Curry SR; Muto CA; Schlackman JL; Pasculle AW; Shutt KA; Marsh JW; Harrison LH
    Clin Infect Dis; 2013 Oct; 57(8):1094-102. PubMed ID: 23881150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the intestinal carriage rates of vancomycin-resistant enterococci (VRE) at a tertiary care hospital in Hungary.
    Franyó D; Kocsi B; Bukta EE; Szabó J; Dombrádi Z
    Folia Microbiol (Praha); 2020 Jun; 65(3):483-490. PubMed ID: 31686360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of colonization and infection with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus and of Clostridium difficile infection in Canadian hospitals.
    Simor AE; Williams V; McGeer A; Raboud J; Larios O; Weiss K; Hirji Z; Laing F; Moore C; Gravel D;
    Infect Control Hosp Epidemiol; 2013 Jul; 34(7):687-93. PubMed ID: 23739072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of vancomycin-resistant enterococci (VRE) in stool specimens submitted for Clostridium difficile toxin testing.
    Özsoy S; İlki A
    Braz J Microbiol; 2017; 48(3):489-492. PubMed ID: 28389190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory-based surveillance for vancomycin-resistant enterococci: utility of screening stool specimens submitted for Clostridium difficile toxin assay.
    Leber AL; Hindler JF; Kato EO; Bruckner DA; Pegues DA
    Infect Control Hosp Epidemiol; 2001 Mar; 22(3):160-4. PubMed ID: 11310695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia.
    Roghmann MC; McCarter RJ; Brewrink J; Cross AS; Morris JG
    Clin Infect Dis; 1997 Nov; 25(5):1056-9. PubMed ID: 9402356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
    Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
    Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of measurement and adjustment for colonization pressure in studies of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and clostridium difficile acquisition.
    Ajao AO; Harris AD; Roghmann MC; Johnson JK; Zhan M; McGregor JC; Furuno JP
    Infect Control Hosp Epidemiol; 2011 May; 32(5):481-9. PubMed ID: 21515979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers.
    Brooks S; Khan A; Stoica D; Griffith J; Friedeman L; Mukherji R; Hameed R; Schupf N
    Infect Control Hosp Epidemiol; 1998 May; 19(5):333-6. PubMed ID: 9613694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
    Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.